Kymera Therapeutics (KYMR) RBC Capital Markets Global Healthcare Conference 2026 summary

Clinical development updates

• KT-621 phase IIb atopic dermatitis study is progressing well, with strong clinician and patient enthusiasm driven by positive phase Ib data and broad awareness efforts.

• Enrollment for KT-621 is on track to complete this year, with data expected by mid-2027; asthma phase IIb started in early 2026 and will complete enrollment next year, with data by end of 2027.

• Open-label extension studies are planned to provide long-term safety and efficacy data, supporting phase III planning.

• Close oversight and real-time monitoring of patient eligibility and site activation are emphasized to ensure quality and cadence of enrollment.

• Broader development plans include future dermatological and respiratory indications, with COPD and EOE as areas of focus.

Safety and therapeutic insights

• KT-621 has shown no notable safety issues in preclinical and early clinical studies, with safety profiles comparable to placebo and no adverse findings in long-term animal studies.

• The molecule’s high potency and selectivity, along with its ability to fully degrade STAT6, are expected to minimize unknown safety events.

• Embryo-fetal development studies in multiple species have shown no evidence of teratogenicity, and regulatory feedback has been reassuring.

• Broader biodistribution of small molecules is seen as an advantage for targeting disease-relevant tissues.

• Open-label extension will provide further long-term safety data as the program advances.

Pipeline and strategic outlook

• IRF5 degrader (KT-579) aims for 90%+ degradation in blood and 50%-80% inhibition of TLR signaling, with phase I MAD data expected in the second half of this year.

• Lupus is prioritized as the initial proof-of-concept indication for KT-579, with IBD also under consideration based on strong genetic and preclinical data.

• Degraders are positioned as superior to inhibitors due to their ability to maintain constant pathway blockade and target all isoforms.

• IRAK4 degrader program (KT-485) is now with Sanofi, with phase I expected to start soon and potential milestones and royalties ahead.

• Early-stage pipeline includes undisclosed targets with significant potential, with more details to be shared later this year.